Adverse effect · AOD-9604

How common is safety in humans with AOD-9604?

C
Grade C — weak human evidenceTrial programme · effect size: not measurable · adverse
Short answerWeak human evidence. Trial programme: enough to be interesting, not enough to count on. Where an effect is seen it is no measurable effect, or none yet shown. Generally well tolerated in the trials — which is the one thing a failed efficacy programme does establish.

What the studies show

Generally well tolerated in the trials — which is the one thing a failed efficacy programme does establish.

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

In context

AOD-9604 is a fragment of human growth hormone developed specifically as an obesity drug. Unlike most peptides sold online, it was tested properly: pooled data across trials covering more than 900 participants found no statistically significant difference in fat mass or body weight against placebo. Development was terminated for lack of efficacy. It is still marketed for fat loss.

AOD-9604 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is AOD-9604 proven to cause safety in humans?
No. The human evidence is weak (Trial programme); LYO grades it C.
What studies are behind the grade?
Generally well tolerated in the trials — which is the one thing a failed efficacy programme does establish.
Is AOD-9604 approved for this?
No. AOD-9604 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for AOD-9604

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →